TWI579278B - 經雙環取代之尿嘧啶類及其用途 - Google Patents

經雙環取代之尿嘧啶類及其用途 Download PDF

Info

Publication number
TWI579278B
TWI579278B TW102116308A TW102116308A TWI579278B TW I579278 B TWI579278 B TW I579278B TW 102116308 A TW102116308 A TW 102116308A TW 102116308 A TW102116308 A TW 102116308A TW I579278 B TWI579278 B TW I579278B
Authority
TW
Taiwan
Prior art keywords
hydrogen
alkyl
compound
trifluoromethyl
formula
Prior art date
Application number
TW102116308A
Other languages
English (en)
Chinese (zh)
Other versions
TW201406744A (zh
Inventor
蔣特 佛斯特奈
詹斯 艾克史達夫
亞歷山大 史托伯
海因瑞奇 米爾
哈娜 泰諾
卡加 齊莫曼
安德里安 特斯提根
德米特力 祖伯夫
賴姆德 卡斯特
詹斯 史蔣伯格
馬汀娜 雪佛
克斯特恩 伯恩根
Original Assignee
拜耳製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 拜耳製藥股份有限公司 filed Critical 拜耳製藥股份有限公司
Publication of TW201406744A publication Critical patent/TW201406744A/zh
Application granted granted Critical
Publication of TWI579278B publication Critical patent/TWI579278B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW102116308A 2012-05-09 2013-05-08 經雙環取代之尿嘧啶類及其用途 TWI579278B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12167231 2012-05-09

Publications (2)

Publication Number Publication Date
TW201406744A TW201406744A (zh) 2014-02-16
TWI579278B true TWI579278B (zh) 2017-04-21

Family

ID=48289199

Family Applications (2)

Application Number Title Priority Date Filing Date
TW102116308A TWI579278B (zh) 2012-05-09 2013-05-08 經雙環取代之尿嘧啶類及其用途
TW106105676A TWI635085B (zh) 2012-05-09 2013-05-08 經雙環取代之尿嘧啶類及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW106105676A TWI635085B (zh) 2012-05-09 2013-05-08 經雙環取代之尿嘧啶類及其用途

Country Status (43)

Country Link
US (5) US9481672B2 (enExample)
EP (2) EP2847190B1 (enExample)
JP (2) JP6141414B2 (enExample)
KR (1) KR102083281B1 (enExample)
CN (2) CN106983751B (enExample)
AP (1) AP2014008096A0 (enExample)
AR (1) AR090994A1 (enExample)
AU (2) AU2013258223B2 (enExample)
BR (1) BR112014028086B1 (enExample)
CA (1) CA2872906C (enExample)
CL (1) CL2014003031A1 (enExample)
CO (1) CO7131375A2 (enExample)
CR (1) CR20140513A (enExample)
CU (1) CU20140129A7 (enExample)
CY (2) CY1118900T1 (enExample)
DK (2) DK2847190T3 (enExample)
DO (1) DOP2014000255A (enExample)
EA (2) EA031222B1 (enExample)
EC (1) ECSP14026138A (enExample)
ES (2) ES2657315T3 (enExample)
HR (2) HRP20160796T1 (enExample)
HU (2) HUE035462T2 (enExample)
IL (2) IL235438A (enExample)
JO (1) JO3290B1 (enExample)
LT (1) LT3045456T (enExample)
MX (2) MX357712B (enExample)
MY (1) MY181828A (enExample)
NO (1) NO3045456T3 (enExample)
NZ (1) NZ701700A (enExample)
PE (1) PE20142301A1 (enExample)
PH (1) PH12014502496A1 (enExample)
PL (2) PL2847190T3 (enExample)
PT (2) PT3045456T (enExample)
RS (2) RS56784B1 (enExample)
SA (1) SA113340533B1 (enExample)
SG (1) SG10202003175QA (enExample)
SI (2) SI3045456T1 (enExample)
TN (1) TN2014000470A1 (enExample)
TW (2) TWI579278B (enExample)
UA (1) UA112897C2 (enExample)
UY (1) UY34797A (enExample)
WO (1) WO2013167495A1 (enExample)
ZA (1) ZA201408146B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
WO2015067651A1 (de) * 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituierte uracile als chymase inhibitoren
LT3066097T (lt) * 2013-11-08 2018-02-12 Bayer Pharma Aktiengesellschaft 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-[(1r)-4-(trifluormetil)-2,3-dihidro-1h-inden-1-il]-1,2,3,4-tetrahidropirimidin-5-karboksirūgšties druskos
CN105980381A (zh) 2013-11-08 2016-09-28 拜耳医药股份有限公司 取代的尿嘧啶及其用途
US20160287599A1 (en) * 2013-11-08 2016-10-06 Bayer Pharma Aktiengesellschaft Substituted 1,2,4-triazine-3,5-diones and the use thereof as chymase inhibitors
WO2017162661A1 (en) 2016-03-22 2017-09-28 Bayer Pharma Aktiengesellschaft 1h-benzo[de]isoquinoline-1,3(2h)-diones
EP3338780A1 (de) 2016-12-20 2018-06-27 Bayer Pharma Aktiengesellschaft Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
CA3061444A1 (en) 2017-04-27 2018-11-01 Bayer Aktiengesellschaft Selective adrenoreceptor .alpha.2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad)
CN112384213A (zh) 2018-05-15 2021-02-19 拜耳公司 用于治疗与神经纤维敏化有关的疾病的1,3-噻唑-2-基取代的苯甲酰胺
CN110229067A (zh) * 2019-06-05 2019-09-13 南京焕然生物科技有限公司 一种2-氨基茚制备方法
WO2021000933A1 (zh) * 2019-07-03 2021-01-07 南京明德新药研发有限公司 作为糜酶抑制剂的嘧啶酮类化合物及其应用
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
CN111440141A (zh) * 2020-05-20 2020-07-24 安徽泽升科技有限公司 一种羟甲基取代芳杂环类化合物的制备方法
CN114685472B (zh) * 2020-12-25 2024-04-26 广东东阳光药业股份有限公司 多取代的尿嘧啶衍生物及其用途
CN114671856B (zh) * 2020-12-25 2023-10-20 广东东阳光药业股份有限公司 多取代的尿嘧啶衍生物及其用途
WO2022135534A1 (zh) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 取代的含氮双环化合物及其用途
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US20250051367A1 (en) * 2021-12-06 2025-02-13 Pretzel Therapeutics, Inc. Heterocycle-containing lonp1 inhibitor compounds, uses and methods
EP4504201A1 (en) 2022-04-05 2025-02-12 Socpra Sciences Santé Et Humaines S.E.C. Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102384A1 (en) * 2000-08-30 2004-05-27 Takashi Deguchi Pyrrolidine derivatives and their use as chymase inhibitor
WO2007150011A2 (en) * 2006-06-23 2007-12-27 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US6114532A (en) 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
WO2001017980A1 (en) 1999-09-03 2001-03-15 Ajinomoto Co., Inc. Novel processes for preparing oxazepine derivatives
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
JP2003017508A (ja) 2001-07-05 2003-01-17 Nec Corp 電界効果トランジスタ
AR038536A1 (es) 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP2003342265A (ja) * 2002-05-22 2003-12-03 Senju Pharmaceut Co Ltd トリアゾリジン誘導体およびその医薬用途
AU2003290735A1 (en) 2002-12-06 2004-06-30 Eli Lilly And Company Inhibitors of monoamine uptake
JP4387360B2 (ja) * 2003-08-22 2009-12-16 帝人ファーマ株式会社 キマーゼ阻害剤を有効成分として含有する薬剤
DE102004004928A1 (de) 2004-01-31 2005-08-18 Bayer Healthcare Ag Dibenzoxazepine II
KR101258504B1 (ko) 2004-03-26 2013-04-26 메틸진 인코포레이티드 히스톤 데아세틸라제의 억제제
US7507748B2 (en) 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
EP1835934A4 (en) 2004-12-23 2010-07-28 Deciphera Pharmaceuticals Llc ENZYME MODULATORS AND TREATMENTS
EP1885369B1 (en) 2005-05-04 2015-09-23 Evotec AG Fused heterocyclic compounds, and compositions and uses thereof
WO2007007161A2 (en) * 2005-07-08 2007-01-18 Orchid Research Laboratories Limited Novel bio-active derivatives
WO2007120339A1 (en) 2005-12-19 2007-10-25 Genentech, Inc. Pyrimidine kinase inhibitors
ATE443061T1 (de) 2006-02-14 2009-10-15 Pfizer Prod Inc Benzoxazinon- und benzoxazepinonoxazolidinone als antibakterielle mittel
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
GB0622472D0 (en) 2006-11-10 2006-12-20 Addex Pharmaceuticals Sa Novel heterocyclic derivatives
EP2114898A2 (en) 2007-02-16 2009-11-11 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
NZ580343A (en) 2007-04-13 2012-03-30 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
EP2205609B1 (de) 2007-10-19 2017-03-29 Boehringer Ingelheim International GmbH Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
CA2722734C (en) * 2008-05-05 2013-11-05 Merck Frosst Canada Ltd. 3,4-substituted piperidine derivatives as renin inhibitors
DE102008030091B4 (de) * 2008-06-25 2011-03-03 Resprotect Gmbh Uracilderivate und deren Verwendung
CA2727340A1 (en) 2008-06-25 2009-12-30 Daiichi Sankyo Company, Limited Carboxylic acid compound
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102384A1 (en) * 2000-08-30 2004-05-27 Takashi Deguchi Pyrrolidine derivatives and their use as chymase inhibitor
WO2007150011A2 (en) * 2006-06-23 2007-12-27 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAMUEL J. DANISHEFSKY ET AL, "Total synthesis of octosyl acid A. Intramolecular Williamson reaction via a cyclic stannylene derivative", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, (19881001), vol. 110, no. 22, doi:10.1021/ja00230a024, ISSN 0002-7863, PAGE 7434 - 7440 *

Also Published As

Publication number Publication date
ES2581537T3 (es) 2016-09-06
CA2872906C (en) 2020-08-04
TWI635085B (zh) 2018-09-11
US20150148340A1 (en) 2015-05-28
US20180256576A1 (en) 2018-09-13
ZA201408146B (en) 2017-01-25
PH12014502496B1 (en) 2015-01-12
EP3045456B1 (de) 2017-10-25
PT2847190T (pt) 2016-07-14
CN106983751A (zh) 2017-07-28
CL2014003031A1 (es) 2015-03-06
AR090994A1 (es) 2014-12-30
RS56784B1 (sr) 2018-04-30
RS54901B1 (sr) 2016-10-31
US20170020875A1 (en) 2017-01-26
MX367599B (es) 2019-08-28
HRP20180125T1 (hr) 2018-02-23
DOP2014000255A (es) 2015-02-27
CN106983751B (zh) 2020-01-07
UA112897C2 (uk) 2016-11-10
CR20140513A (es) 2014-12-02
JP6367421B2 (ja) 2018-08-01
SG10202003175QA (en) 2020-05-28
EA201492040A1 (ru) 2015-12-30
CY1118900T1 (el) 2018-01-10
CY1119840T1 (el) 2018-06-27
CN104395310B (zh) 2017-05-03
MY181828A (en) 2021-01-08
JP2017160242A (ja) 2017-09-14
SI2847190T1 (sl) 2016-08-31
NZ701700A (en) 2016-09-30
SA113340533B1 (ar) 2015-10-12
LT3045456T (lt) 2018-02-12
BR112014028086B1 (pt) 2021-09-21
DK3045456T3 (da) 2018-01-29
EP2847190A1 (de) 2015-03-18
WO2013167495A1 (de) 2013-11-14
EA201790032A1 (ru) 2017-05-31
IL253950A0 (en) 2017-10-31
TN2014000470A1 (en) 2016-03-30
IL253950B (en) 2019-07-31
UY34797A (es) 2013-11-29
KR102083281B1 (ko) 2020-05-29
EA031222B1 (ru) 2018-12-28
TW201406744A (zh) 2014-02-16
CU20140129A7 (es) 2015-02-26
EP3045456A1 (de) 2016-07-20
IL235438A (en) 2017-08-31
PL3045456T3 (pl) 2018-03-30
HUE035462T2 (en) 2018-05-02
AU2017265047A1 (en) 2017-12-14
TW201734007A (zh) 2017-10-01
US20170020876A1 (en) 2017-01-26
MX357712B (es) 2018-07-20
CA2872906A1 (en) 2013-11-14
US10300062B2 (en) 2019-05-28
BR112014028086A2 (pt) 2020-12-01
PH12014502496A1 (en) 2015-01-12
AU2013258223A1 (en) 2014-11-27
JO3290B1 (ar) 2018-09-16
DK2847190T3 (en) 2016-07-25
US9481672B2 (en) 2016-11-01
US20200061063A1 (en) 2020-02-27
AP2014008096A0 (en) 2014-12-31
ECSP14026138A (es) 2015-12-31
JP6141414B2 (ja) 2017-06-07
HUE029366T2 (en) 2017-02-28
EP2847190B1 (de) 2016-04-06
AU2017265047B2 (en) 2019-04-18
EA030383B1 (ru) 2018-07-31
CO7131375A2 (es) 2014-12-01
JP2015516000A (ja) 2015-06-04
SI3045456T1 (en) 2018-03-30
CN104395310A (zh) 2015-03-04
PE20142301A1 (es) 2014-12-19
HRP20160796T1 (hr) 2016-08-12
KR20150016548A (ko) 2015-02-12
PT3045456T (pt) 2018-01-30
AU2013258223B2 (en) 2017-11-09
MX2014013571A (es) 2014-12-08
EA030383B9 (ru) 2018-12-28
PL2847190T3 (pl) 2016-12-30
HK1202873A1 (en) 2015-10-09
NO3045456T3 (enExample) 2018-03-24
US9949978B2 (en) 2018-04-24
US9949977B2 (en) 2018-04-24
ES2657315T3 (es) 2018-03-02

Similar Documents

Publication Publication Date Title
TWI579278B (zh) 經雙環取代之尿嘧啶類及其用途
CN112469412A (zh) 取代的二氢吡唑并吡嗪甲酰胺衍生物
HK1224288A1 (zh) 作为类糜蛋白酶抑制剂的取代的尿嘧啶
TW201900616A (zh) 經取代之ｎ－芳基乙基－２－胺基喹啉－４－甲醯胺及其用途
CN105980381A (zh) 取代的尿嘧啶及其用途
HK1202873B (en) Bicyclically substituted uracils and the use thereof
HK1224663A1 (zh) 取代的尿嘧啶及其用途